Nyxoah (NASDAQ:NYXH) Stock Rating Upgraded by Cantor Fitzgerald

Nyxoah (NASDAQ:NYXH) was upgraded by analysts at Cantor Fitzgerald to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Several other brokerages have also recently weighed in on NYXH. Piper Sandler reissued an “overweight” rating and issued a $9.00 price objective (down from $12.00) on shares of Nyxoah in a research note on Friday, November 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nyxoah in a report on Monday, December 29th. Finally, Stifel Nicolaus decreased their price target on Nyxoah from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday, January 29th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.67.

Nyxoah Stock Down 5.6%

Shares of NASDAQ NYXH opened at $3.72 on Wednesday. The company has a 50 day simple moving average of $4.65 and a 200 day simple moving average of $5.07. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.70 and a quick ratio of 1.41. Nyxoah has a 1 year low of $3.66 and a 1 year high of $11.87. The firm has a market cap of $126.70 million, a PE ratio of -1.49 and a beta of 1.56.

Institutional Investors Weigh In On Nyxoah

Several large investors have recently added to or reduced their stakes in NYXH. Franklin Resources Inc. boosted its holdings in shares of Nyxoah by 0.9% during the 2nd quarter. Franklin Resources Inc. now owns 294,990 shares of the company’s stock worth $2,207,000 after buying an additional 2,655 shares in the last quarter. Rossmore Private Capital increased its stake in shares of Nyxoah by 12.6% in the 3rd quarter. Rossmore Private Capital now owns 132,746 shares of the company’s stock valued at $616,000 after acquiring an additional 14,806 shares in the last quarter. Kovack Advisors Inc. increased its stake in shares of Nyxoah by 67.8% in the 3rd quarter. Kovack Advisors Inc. now owns 97,039 shares of the company’s stock valued at $446,000 after acquiring an additional 39,212 shares in the last quarter. Heights Capital Management Inc. acquired a new position in shares of Nyxoah during the 4th quarter valued at $3,575,000. Finally, Deutsche Bank AG boosted its stake in Nyxoah by 40.0% during the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock worth $161,000 after acquiring an additional 10,000 shares in the last quarter.

About Nyxoah

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.